3 active not recruiting, 2 completed, 1 not yet recruiting, 1 terminated. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Completed 2, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 3 | Active not recruiting 2, Terminated 1 |
Follow NETRIS Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer NP137 - Pancreatic Cancer | Phase 1 | Not yet recruiting | Aram Hezel | 25 | 2026-09-01 | 2026-02-05 |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Terminated | Centre Leon Berard | 1 | 2024-09-11 | 2025-02-20 |
| Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma NP137, Oxaliplatin, Irinotecan - Pancreatic Ductal Adenocarcinoma | Phase 1 | Completed | University Hospital, Grenoble | 43 | 2023-03-28 | 2026-05-19 |
| Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC NP137, Atezolizumab, Bevacizumab - Hepatocellular Carcinoma | Phase 1 | Active not recruiting | University Hospital, Grenoble | 43 | 2023-03-15 | 2026-05-20 |
| NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies NP137, anti-PD-1/PD-L1 - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 2 | Active not recruiting | Centre Leon Berard | 57 | 2023-01-06 | 2026-09-25 |
| GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab NP137, Pembrolizumab, Paclitaxel - Endometrial Carcinoma, Cervix Carcinoma | Phase 1 / Phase 2 | Active not recruiting | NETRIS Pharma | 240 | 2020-12-14 | 2026-11-16 |
| First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors NP137 DL and RP2D - Advanced Solid Tumor, Endometrial Carcinoma | Phase 1 | Completed | Centre Leon Berard | 70 | 2017-01-09 | 2022-07-25 |
Endometrial Neoplasms (2) · Carcinoma, Hepatocellular (1) · Leukemia, Myeloid, Acute (1) · Pancreatic Neoplasms (1) · Uterine Cervical Neoplasms (1)
netrin-1 inhibitor NP137 (6) · Azacitidine (1) · Bevacizumab (1) · Carboplatin (1) · Irinotecan (1) · Oxaliplatin (1) · Paclitaxel (1) · atezolizumab (1) · pembrolizumab (1) · venetoclax (1)
France (6) · United States (1)
Aram Hezel (1)
PMID 34470826, PMID 37532929, PMID 42020751
2015 (1)